Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
KarXT · 21 trials · 13 indications
The YMRS comprised of 11 items that assess the severity of manic symptoms. All items are given a severity rating, with 4 items graded from 0 to 8 (irritability, speech, thought content, and disruptive/aggressive behavior), and the remaining 7 items are graded from 0 to 4 points. The highest score obtainable on the YMRS is 60 and the higher the number the greater the number of symptoms and/or the greater their severity.
Open-label extension (OLE) Part
Number of participants with Treatment Emergent Adverse Events (TEAEs) from first dose to end of study follow up. An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after signing of informed consent, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory test result), symptom, or disease temporally associated with the study intervention.
Number of participants with TEAEs at the end of period 1 and period 2. An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after signing of informed consent, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory test result), symptom, or disease temporally associated with the study intervention.
Number of participants with TEAEs at the end of period 1 and period 2. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.
Number of participants with TEAEs leading to treatment discontinuation.
The number of participants experiencing adverse events related to procholinergic symptoms (believed to be associated with xanomeline) and anticholinergic symptoms (believed to be associated with trospium) symptoms. Examples of procholinergic symptoms include vomiting, nausea, diarrhea, sweating and hyper-salivation. Examples of anticholinergic include dizziness, confusion, hallucinations, and somnolence.
Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions scale includes 2 domains from the NPI-C scale, namely, hallucinations and delusions. These 2 domains include the following number of items to be rated by the clinician: Hallucinations, 7 items (maximum score = 21) and Delusions, 8 items (maximum score = 24). The maximum score for the NPI-C: H+D scale is 45. Higher scores on this scale indicate worse outcomes.
The number and percentage of participants with TEAEs will be determined
Part 1
Part 1
Part 1
Part 1
Part 1
Part 1
Part 2
Part 2
Part 2
Part 2
Part 2
Part 2
Part 2
| Arm | Type | Description |
|---|---|---|
| KarXT + KarX-EC Arm | EXPERIMENTAL | - |
| Placebo | EXPERIMENTAL | - |
| Administration of KarXT for Schizophrenia | EXPERIMENTAL | - |
| Administration of KarXT for Autism-related Irritability | EXPERIMENTAL | - |
| KarXT | EXPERIMENTAL | - |
| KarXT+KarX-EC | EXPERIMENTAL | - |
| KarXT + KarX-EC | ACTIVE_COMPARATOR | - |
| KarXT or Adjuvant KarXT | EXPERIMENTAL | - |
| Administration of KarXT | ACTIVE_COMPARATOR | - |
| KarXT on empty stomach and with food | EXPERIMENTAL | - |
| Part 1 | EXPERIMENTAL | - |
| Part 2 | EXPERIMENTAL | - |
| Part 3 | EXPERIMENTAL | - |
| Part 1a | EXPERIMENTAL | - |
| Cohort 1 | EXPERIMENTAL | - |
| Cohort 2 | EXPERIMENTAL | - |
| Cohort 3 | EXPERIMENTAL | - |
| Group A | EXPERIMENTAL | - |
| Group B | EXPERIMENTAL | - |
| Group C | EXPERIMENTAL | - |
| Group D | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| KarXT | DRUG | Specified dose on specified days |
| KarX-EC | DRUG | Specified dose on specified days |
| KarXT + KarX-EC Matching Placebo | DRUG | Specified dose on specified days |
| KarXT + KarX-EC Arm Matching Placebo | DRUG | Specified dose on specified days |
| KarXT Matching Placebo | OTHER | Specified dose on specified days |
| Placebo | OTHER | Specified dose on specified days |
| Lithium | DRUG | Therapeutic dose |
| Valproate | DRUG | Therapeutic dose |
| Lamotrigine | DRUG | Therapeutic dose |
| Midazolam | DRUG | Specified dose on specified days |
| Fexofenadine | DRUG | Specified dose on specified days |
| Digoxin | DRUG | Specified dose on specified days |
| Omeprazole | DRUG | Specified dose on specified days |
Inclusion Criteria * Participants must have a confirmed diagnosis of ASD, as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria, confirmed by the K-SADS-PL and must be experiencing symptoms of irritability. * Participants must have...